Diligence memo · auto-generated · as of July 3, 2026
Sendero Biotechnology, Inc.
Sendero Biotechnology, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Sendero Biotechnology, Inc. operates in Biotechnology, based in ROCHESTER.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sendero Biotechnology, Inc. has raised $7.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.3M on 2023-04-15.
Most recent recorded round closed around 2023-04-15.
Valuation (modeled)modeled
Provath models Sendero Biotechnology, Inc. at approximately $69M (range $8.0M–$198M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.56× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 3.2 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 50% of Biotechnology peers (4293 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.